Get started

AMLX

Insiders loading - BIG GAP FILL POTENTIAL - AMLX - BIOTECH PLAYInsiders high level are loading up shares in the sub 3.00 area, I will personally scoop up shares between 2.99-2.54 Below that this plan is invalid. Stop placed at 2.54. HUGE POTENTIAL FOR GAP FILL ON ANY POSITIVE NEWS. GOING THROUGH NO MANS LAND WITH VOLUME MEANS HUGE POTENTAL. Because these things can be event based set your limit sells at numbers that make sense for you. I will be cutting 35% around 4.30-4.40. Might buy back if it drops to 3.80s before any gap filling takes place. Looking at a 43% upside from these levels to recent highs and if a bullish event-based volume day happens... Well, 6.51 is the next stop, and possibly $11. Not a bad risk/reward ratio here. Maybe the insiders, CFOs directors know something we don't just yet.
NASDAQ:AMLXLong
by mortimerkylej
2
Amylyx Stock Down With Over 82%, After Pivotal ALS Drug FailureAmylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measuring the severity of amyotrophic lateral sclerosis, the longhand name for ALS. In this disease, nerve cells break down, reducing muscle function. The Food and Drug Administration approved Relyvrio based on a single study in September 2022. But Amylyx ( NASDAQ:AMLX ) continued on with a Phase 3 study. Now, Amylyx ( NASDAQ:AMLX ) is deciding whether to voluntarily pull the drug from the market in the U.S. and Canada. In Canada, it sells under the brand name Albrioza. Technical Analysis On today's stock market, Amylyx ( NASDAQ:AMLX ) stock plummeted 82.9% to 3.36. Shares undercut their 50-day and 200-day moving averages, MarketSurge.com shows. That put shares at a record low. Way Forward For Amylyx Stock? It's important to note that Relyvrio failed to make a difference across multiple measures, including the key goal of the study: improvement on the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. The company tested Relyvrio over 48 weeks. Secondary measures of the study also flopped. Amylyx ( NASDAQ:AMLX ) says it now expects to have the results of its study in Wolfram syndrome patients in the second quarter.
NASDAQ:AMLXShort
by DEXWireNews